Detail akcie Avaln Globocare Rg online

Business Summary: Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Avalon Globocare Corp revenues increased 6% to $1.1M. Net loss applicable to common stockholders increased from $5.2M to $16M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Professional fees - Balancing value increase from $1.2M to $4.4M (expense).